Regeneron Pharmaceuticals' Assets Average rose 734.93% to $40.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $40.4 billion, marking a year-over-year increase of 734.93%. This contributed to the annual value of $39.2 billion for FY2025, which is 1055.69% up from last year.
According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Assets Average is $40.4 billion, which was up 734.93% from $39.2 billion recorded in Q3 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Assets Average peaked at $40.4 billion during Q4 2025, and registered a low of $17.5 billion during Q1 2021.
Over the past 5 years, Regeneron Pharmaceuticals' median Assets Average value was $30.9 billion (recorded in 2023), while the average stood at $30.8 billion.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Assets Average surged by 4822.6% in 2022, and later skyrocketed by 660.95% in 2025.
Regeneron Pharmaceuticals' Assets Average (Quarter) stood at $24.6 billion in 2021, then increased by 15.86% to $28.4 billion in 2022, then increased by 14.68% to $32.6 billion in 2023, then increased by 15.26% to $37.6 billion in 2024, then rose by 7.35% to $40.4 billion in 2025.
Its Assets Average stands at $40.4 billion for Q4 2025, versus $39.2 billion for Q3 2025 and $37.9 billion for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value